Therapeutic Asset Ratings
766 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
[68ga]ga-nota-t4
Prostate Cancer
RenJi Hospital
P2/3
CCC
(48)
[68ga]ga-nota-t4
Neoplasm
RenJi Hospital
P2/3
CCC
(48)
[68ga]p16-093
Prostate Cancer
Five Eleven Pharma, Inc.
P1/2
CCC
(48)
68ga-p16-093
Prostate Cancer
Peking Union Medical College Hospital
P2/3
CCC
(48)
68ga-p16-093
Prostate Adenocarcinoma
First Affiliated Hospital of Fujian Medical University
P1/2
CCC
(48)
CAM-H2
Advanced/Metastatic HER2-positive Breast, Gastric, Gastroesophageal Junction Cancer With Disease Progression Following Anti-HER2 Standard of Care Treatment
Precirix
P1/2
CCC
(48)
Lutetium-177-Dotaga-Iac
Breast Cancer
Advanced Imaging Projects, LLC
P1/2
CCC
(48)
Rhenium Liposome Treatment
Glioma
Plus Therapeutics
P1/2
CCC
(48)
Tb-Psma-I&T
Prostate Cancer
Rabin Medical Center
P1/2
CCC
(48)
Yttrium-90
Disease Related To Solid Organ Transplantation
University Health Network, Toronto
P1/2
CCC
(48)
123i-att001
Glioblastoma
Theragnostics Ltd
P1
CC
(47)
177Lu-LNC1004
Solid Tumor, Unspecified, Adult
Yantai LNC Biotechnology Singapore PTE. LTD.
P1
CC
(47)
[18f]ucb-2897
Multiple System Atrophy
Invicro
P1
CC
(47)
[68ga]ga-oncofap administration
Esophageal Cancer
Philogen S.p.A.
P1
CC
(47)
68ga-lnc1007
Cancer
Yantai LNC Biotechnology Singapore PTE. LTD.
P1
CC
(47)
68ga-r10602
Hormone Receptor-Positive Breast Cancer
Radionetics Oncology
P1
CC
(47)
Gallium-68 Labelled Fap-2286
Myocardial Fibrosis
Thomas Hope
P1
CC
(47)
[111in]-fpi-1967
Urinary Bladder Carcinoma
Fusion Pharmaceuticals Inc.
P1/2
CC
(47)
177lu-betabart
Castration-Resistant Prostate Carcinoma
Radiopharm Theranostics, Ltd
P1/2
CC
(47)
177lu-betabart
Triple-Negative Breast Carcinoma
Radiopharm Theranostics, Ltd
P1/2
CC
(47)
177lu htk03170
Castration-Resistant Prostate Carcinoma
British Columbia Cancer Agency
P1/2
CC
(47)
[177lu]lu-dpi-4452
Non-Small Cell Squamous Lung Carcinoma
ITM Oncologics GmbH
P1/2
CC
(47)
[177lu]lu-sn201
Unresectable Solid Tumor
Spago Nanomedical AB
P1/2
CC
(47)
[212pb]pb-mp0712
Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)
Molecular Partners AG
P1/2
CC
(47)
[212pb]vmt01
Melanoma
Perspective Therapeutics
P1/2
CC
(47)
Showing 176 to 200 of 766 assets
Previous
Page 8 of 31
Next